NCT00477100 Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
| NCT ID | NCT00477100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Inflammatory Breast Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2007-04-17 |
| Primary Completion | 2030-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2007-04-17 with a primary completion date of 2030-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial studies the biospecimen and medical data collection in creating a research tissue registry in patients with inflammatory or invasive breast cancer. Collecting medical data and storing samples of blood, tissue, and stool from patients with inflammatory breast cancer to study in the laboratory may help doctors find better ways to treat and study inflammatory breast cancer in the future.
Eligibility Criteria
Inclusion Criteria: * Patients with clinical diagnosis of primary inflammatory breast cancer (IBC), second primary IBC, or highly suspicious for IBC (MD Anderson patients only). * Histological diagnosis of invasive breast cancer, or highly suspicious for IBC (MD Anderson patients only) but pending breast cancer diagnosis. * Be either newly diagnosed, or highly suspicious for IBC (MD Anderson patients only) \[Cohort I\] or have paraffin blocks or up to 20 unstained slides of each representative block(s) from the time of initial diagnosis of IBC(i.e. core biopsy and punch biopsy) and/or from mastectomy (Cohort II-MD Anderson patients only) * Age \> 18 years * Able to provide informed consent Exclusion Criteria:
Contact & Investigator
VIcente Valero, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT00477100 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Inflammatory Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00477100 currently recruiting?
Yes, NCT00477100 is actively recruiting participants. Contact the research team at jwilley@mdanderson.org for enrollment information.
Where is the NCT00477100 trial being conducted?
This trial is being conducted at Gilbert, United States, La Jolla, United States, Greeley, United States, Jacksonville, United States and 6 additional locations.
Who is sponsoring the NCT00477100 clinical trial?
NCT00477100 is sponsored by M.D. Anderson Cancer Center. The principal investigator is VIcente Valero, MD at M.D. Anderson Cancer Center. The trial plans to enroll 1,200 participants.